For the past four decades, oral antiretroviral therapy for HIV has required daily doses. Long-acting injectable cabotegravir and rilpivirine has ended that obligation,1 requiring an injection every month or every 2 months. In The Lancet, Amy E Colson and colleagues2 report ISLEND-2, a randomised, open-label trial in which 626 virologically suppressed adults with HIV-1 either switched to a once-weekly, single oral tablet containing islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a capsid inhibitor, or continued daily standard-of-care therapy.
Kaynak: The Lancet
